Josafath Alan Huerta-Rojas, Gabriela Bravo-de la Rosa, Jesús Texis-Ramírez, Itari Teresa Reyes-Tobón
{"title":"[Events attributable to Vaxzevria vaccine in pregnant women from a first-level hospital in Puebla].","authors":"Josafath Alan Huerta-Rojas, Gabriela Bravo-de la Rosa, Jesús Texis-Ramírez, Itari Teresa Reyes-Tobón","doi":"10.5281/zenodo.12667969","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>COVID-19 is a severe acute respiratory syndrome caused by SARS-CoV-2. This disease had a high mortality rate and turned into a pandemic, which is why it was considered a severe public health problem. In this context, pregnant patients were a vulnerable group and, consequently, an effective vaccine was necessary.</p><p><strong>Objective: </strong>To categorize the events attributable to the application of Vaxzevria vaccine in pregnant patients.</p><p><strong>Material and methods: </strong>Retrospective, cross-sectional, descriptive and observational study carried out at No. 55 Family Medicine Unit in Puebla, Puebla. 300 patients between 15 and 44 years of age who received the first dose of Vaxzevria vaccine were included. The Format of Notification of Events Presumably Attributable to Vaccination was reviewed.</p><p><strong>Results: </strong>The most representative general symptoms were headache in 44.3%; fever in 30.7%; asthenia and adynamia in 19.3%; adynamia in 19%, and limitation of movement in 3%. Concerning local symptoms and signs, 23% presented localized pain on the site where the vaccine was administered. Finally, regarding systemic symptoms, 21.7% had arthralgias and 20.7% myalgias.</p><p><strong>Conclusions: </strong>The symptoms and signs were of less severity for pregnant patients, and resolved in a few days, which is why it was safe the administration of Vaxzevria vaccine.</p>","PeriodicalId":94200,"journal":{"name":"Revista medica del Instituto Mexicano del Seguro Social","volume":"62 5","pages":"1-6"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista medica del Instituto Mexicano del Seguro Social","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5281/zenodo.12667969","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: COVID-19 is a severe acute respiratory syndrome caused by SARS-CoV-2. This disease had a high mortality rate and turned into a pandemic, which is why it was considered a severe public health problem. In this context, pregnant patients were a vulnerable group and, consequently, an effective vaccine was necessary.
Objective: To categorize the events attributable to the application of Vaxzevria vaccine in pregnant patients.
Material and methods: Retrospective, cross-sectional, descriptive and observational study carried out at No. 55 Family Medicine Unit in Puebla, Puebla. 300 patients between 15 and 44 years of age who received the first dose of Vaxzevria vaccine were included. The Format of Notification of Events Presumably Attributable to Vaccination was reviewed.
Results: The most representative general symptoms were headache in 44.3%; fever in 30.7%; asthenia and adynamia in 19.3%; adynamia in 19%, and limitation of movement in 3%. Concerning local symptoms and signs, 23% presented localized pain on the site where the vaccine was administered. Finally, regarding systemic symptoms, 21.7% had arthralgias and 20.7% myalgias.
Conclusions: The symptoms and signs were of less severity for pregnant patients, and resolved in a few days, which is why it was safe the administration of Vaxzevria vaccine.